People · Operator
Named in public records as an officer, director or promoter · active 2009–2026 · Other Health Care, Biotech / Pharma, Biotechnology
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Endologix Inc /De/ | — | Other Health Care | Series D+ | $420.0M | $4.8B | 2010 |
| Arcadia Biosciences, Inc. | — | Biotech / Pharma | Series B | $58.4M | $7.8M | 2018 |
| Clarient, Inc | — | Other Health Care | Series B | $40.0M | $241.7M | 2009 |
| CHF Solutions, Inc. | — | Biotechnology | Series A | $33.0M | $17.1M | 2013 |
Gregory D. Waller at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Gregory D. Waller on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Andrew Adams | 1 | 13 |
| Paul Buckman | 1 | 10 |
| David Collier | 1 | 8 |
| Ann H. Lamont | 1 | 6 |
| James A. Datin | 1 | 6 |
| David A. Rosa | 1 | 5 |
| Jon Salveson | 1 | 5 |
| John L. Erb | 1 | 5 |
| Leslie V. Norwalk | 1 | 5 |
| John McDermott | 1 | 5 |
| David Rosa | 1 | 5 |
| Mark Wong | 1 | 5 |
| John Onopchenko | 1 | 4 |
| Robert D Mitchell | 1 | 4 |
| JEFFREY S. MATHIESEN | 1 | 4 |
| Paul A Buckman | 1 | 3 |
| Stephen T. Zarrilli | 1 | 3 |
| Jeffrey F. O'Donnell | 1 | 3 |
| John Erb | 1 | 3 |
| Mark Harvey | 1 | 3 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.